Incyte reports positive Phase 3 results for povorcitinib in nonsegmental vitiligo, plans FDA filing
read at Endpoints ↗Positive readoutPositive
Incyte announced that its oral JAK1 inhibitor povorcitinib achieved positive outcomes in two Phase 3 trials targeting nonsegmental vitiligo.
The studies met their primary endpoints, demonstrating statistically significant repigmentation compared with placebo.
On the basis of these data, Incyte intends to file a regulatory submission to seek approval of the pill for this chronic skin disorder.
The company said the results could broaden therapeutic options for patients who have limited treatments today.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Incyte claims double Phase 3 win in vitiligo, will file for approval”
read at Endpoints ↗84 words · retrieved Apr 28
comments(0)
5-min edit window · permanent after that